Things are moving forward nicely and fast now and all ingredients are now assembled to make a great event out of the second NP2D congress in Zermatt in less than two months. As you will find out below, we already have a nice panel of participants, and we expect more every day now !

We have the confirmed participation of delegations from major companies such as Airmid LLC (USA), Alecor (Australia), Altana Pharma AG (Germany), Ambrilia Biopharma Inc. (Canada), AM-Pharma (Netherlands), AplaGen GmbH (Germany), Argolyn Bioscience Inc. (USA), Atheris Laboratories (Switzerland),  Chaperone Technologies (USA), Chromatide Ltd, (exhibitor, UK), Cyclagen (Australia), Bachem (Switzerland and USA), DBV Technologies (France), Debiopharm (Switzerland), DiagnoSwiss Sàrl (Switzerland), Domantis Ltd. (UK), Eli Lilly & Co. (sponsor, USA), Evolutec (UK), FunZyme Biotechnologies (Switzerland), Gemac Pharma (France), Genepep (France), Genzyme Pharmaceuticals (Switzerland and USA), Kalthera (Australia), KeySep S.à.r.l (Switzerland), Lonza (Sponsor, Switzerland), Med Discovery SA (Switzerland), Metabolic Pharmaceuticals Ltd. (Australia), Nektar Therapeutics (USA), Novo Nordisk (Denmark), Novozymes (Denmark), Pentapharm (Switzerland), Peptisyntha SA (Belgium), Pierre-Fabre Laboratories (France), Polypeptide Laboratoires (exhibitor, Denmark), Polyphor Ltd. (Switzerland), Procyon Biopharma Inc. (Canada),  Senn Chemicals (Switzerland), Xenome Ltd (Australia) and John Wiley (partner, UK).

Major Universities from all continents (Geneva, Glasgow, Irvine California, Chicago, Frederiksberg, Karlsruhe, Melbourne, Oslo, Queensland, La Sapienza, Sherbrooke, Siena, Singapore, Tashkent etc.) and institutions such as the J. Craig Venter Institute (USA), the Georg Speyer Haus (Germany), the Howard Florey Institute (Australia), the Commissariat à l’Energie Atomique (France), the Mintaka Foundation for Medical Research, the Strathclyde Institute for Drug Research (UK) and the Technion Institute (Israel) will be present with outstanding scientific contributions.

Additionally, venture capital companies such as SPEF Venture (Natexis Private Equity, France), Katzarov (Switzerland), TVM (Germany), as well as Nlight! Marketing & Communication in Life Sciences (Switzerland), and local biotech incubators.

We are convinced that this will be an excellent opportunity for your organisation and give you access to great networking opportunities.

The event will bring together a broad range of scientists from the academia and from the industry who share the same interest for peptide based drugs, even though they come from different horizons and from all around the world. Amongst all participants you will for example have a chance to meet with the following key opinion leaders:

Prof. Paul Alewood, University of Queensland, Australia
Dr Mimoun Ayoub, Genzyme Pharmaceuticals, Basel, Switzerland
Dr Thierry Baussant, KeySep S.à.r.l, Switzerland
Dr Alain Beck, Centre d'Immunologie Pierre Fabre, France
Dr Corina Borghouts-Heinz, Georg Speyer Haus, Germany
Dr Daniel Bourgin, Lonza, Basel, Switzerland
Dr Luisa Bracci, University of Siena, Italy
Dr Michael J. Brownstein, J. Craig Venter Institute, USA
Dr Peter Cassidy, University of Queensland, Australia
Prof. George Chandy, University of California Irvine & Airmid Ltd, USA
Dr José de Chastonay, Bachem Americas, California, USA
Dr Claude Colin, Polypeptide Laboratories, Hillerod, Denmark 
Prof. David Craik, University of Queensland, Australia
Dr David Deperthes, Med Discovery SA, Switzerland
Dr Thomas Dix, Argolyn Bioscience Inc., USA
Dr Mohamed Elayeb, Institut Pasteur de Tunis, Tunisie
Dr Emanuel Escher, University of Sherbrooke, Canada
Dr Ian Evans, Evolutec, UK
Dr Philippe Favreau, Atheris Laboratories, Switzerland
Dr Olga Federova, Institute of Microbiology, Uzbekistan
Dr Anne Fogli, Atheris Laboratories, Switzerland
Dr Frank Gafner, Pentapharm AG, Basel, Switzerland
Dr Patrick Garrouste, Debio Group, Switzerland
Dr Michel Geffard, Gemac Pharma, France
Dr Nicolas Gilles, CEA-Saclay, Gif-sur-Yvette, France
Prof. Ponnampalan Gopalakrishnakone, University of Singapore, Singapore
Dr Udo Haberl, AplaGen GmbH, Baesweiler, Germany
Dr Paul R. Hansen, Royal Veterinary and Agricultural University Frederiksberg, Denmark
Prof. Alan Harvey, Strathclyde Institute for Drug Research, UK 
Dr Peter Hoffmann, Genzyme Pharmaceuticals, Cambridge, USA
Dr Irmgard Irminger-Finger, University Hospitals Geneva HUG, Switzerland
Dr Emmanuel Jelsch, Katzarov SA, Switzerland
Prof. Stephen B.H. Kent, University of Chicago, USA
Dr Vladimir Khavinson, St. Petersburg Institute of Bioregulation and Gerontology, Russia
Mrs Emilie Le Claire, Pentapharm AG, Basel, Switzerland
Dr Guenther Loidl, Bachem AG, Bubendorf, Switzerland
Dr Maria Luisa Mangoni, Università La Sapienza, Roma
Dr Naziha Marrakchi, Institut Pasteur, Tunis
Dr John P. Mayer, Eli Lilly and Co., USA
Prof. André Ménez, CEA-Saclay, Paris, France
Dr Laure Menin, Atheris Laboratories, Switzerland
Dr Sophie Michalet, Atheris Laboratories, Switzerland
Dr George Miljanich, Airmid LLC, USA
Dr Michel Mollard, SPEF Venture, Paris, France
Dr Amram Mor, Technion Institute, Israel
Dr Inge Mühldorfer, Altana Pharma AG, Germany
Dr Per Holse Mygind, Novozymes A/S, Denmark
Dr John Nissen-Meyer, University of Oslo, Norway
Dr Dimitrios Noukakis, N!light, Switzerland
Prof. Robin Offord, University of Geneva, Switzerland
Dr Laszlo Otvos, Wistar Institute & OLPE Pharmaceutical Consultants, Philadelphia, USA
Dr Chandra Panchal, Procyon Biopharma Inc., Canada
Dr Michael Pennington, Bachem Bioscience, Pennsylvania, USA
Mrs Anna Perchuc, Pentapharm AG, Basel, Switzerland
Dr Frédéric Perret, Atheris Laboratories, Switzerland
Dr Karine Puget, Genepep, France
Dr Inna Radzishevsky, Technion Institute, Israel
Dr Sylvie Rebuffat, National Museum of Natural History, France
Dr Jennifer Riggs-Sauthier, Nektar Therapeutics, USA
Dr Jorge Ronco, DBV Technologies, France
Prof. Keith Rose, University Medical School of Geneva, Switzerland
Dr Joël Rossier, DiagnoSwiss Sàrl, Switzerland
Dr Martin Röthlisberger, John Wiley & Sons, UK
Mrs Hélène Serrano, Atheris Laboratories, Switzerland
Dr Martin Schneider, SennChemicals AG, Switzerland
Dr Reto Schöni, Pentapharm AG, Basel, Switzerland
Dr Marie Skovgaard, Novo Nordisk A/S, Denmark
Dr Neil Thompson, Polypeptide Laboratories, Hillerod, Denmark 
Dr Csaba Tömböly, Institute of Biochemistry, Szeged, Hungary
Prof. Geoffrey W. Tregear, Howard Florey Institute, Australia
Prof. Anne Ulrich, University of Karlsruhe and Forschungszentrum Karlsruhe, Germany
Dr Markwin Velders, AM-Pharma, Netherlands
Dr Jan Vrijbloed, Polyphor Ltd, Switzerland
Dr Christina Wedemeyer, Genzyme Pharmaceuticals, Switzerland
Dr Astrid Weiss, Institute for Biomedical Research, Germany
Dr Donald A Wellings, Chromatide Ltd, Cheshire, UK
Dr Timothy Wells, Serono International, Switzerland
Dr Werner Wolf, TVM, Munich, Germany